Pazdur R, Jackson D, Shepherd B, Saddler D, Font L, McCardell M, Myers P, Schmidt S
Section of Gastrointestinal Oncology and Digestive Diseases, University of Texas M.D. Anderson Cancer Center, Houston.
Oncol Nurs Forum. 1991 Jan-Feb;18(1 Suppl):11-7.
Improved response rates in metastatic colorectal carcinoma recently have been observed for the combination of 5-fluorouracil (5-FU) and recombinant interferon alfa-2a (rIFN), compared to those obtained in historical trials of single-agent 5-FU. The mechanism of interaction between these agents has not been explored adequately but may relate to biochemical modulation of 5-FU by rIFN. Toxicities resulting from this combination have included fever, chills, myalgias, granulocytopenia, mucositis, diarrhea, skin rash, neurological symptoms, and hand-foot syndrome. Future studies of 5-FU with rIFN should investigate schedules aimed at reducing toxicity without compromising efficacy and also should explore mechanisms of enhanced activity.
与既往单药5-氟尿嘧啶（5-FU）试验相比，最近观察到5-氟尿嘧啶（5-FU）与重组干扰素α-2a（rIFN）联合应用于转移性结直肠癌时缓解率有所提高。这些药物之间的相互作用机制尚未得到充分研究，但可能与rIFN对5-FU的生化调节有关。这种联合用药产生的毒性包括发热、寒战、肌痛、粒细胞减少、粘膜炎、腹泻、皮疹、神经症状和手足综合征。未来关于5-FU与rIFN的研究应探索旨在在不影响疗效的情况下降低毒性的给药方案，还应探究活性增强的机制。
